1037 related articles for article (PubMed ID: 26503995)
1. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
Dempke WC; Sellmann L; Fenchel K; Edvardsen K
Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
[TBL] [Abstract][Full Text] [Related]
2. Addressing the unmet need in lung cancer: The potential of immuno-oncology.
Scagliotti GV; Bironzo P; Vansteenkiste JF
Cancer Treat Rev; 2015 Jun; 41(6):465-75. PubMed ID: 25936526
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
Anagnostou VK; Brahmer JR
Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
[TBL] [Abstract][Full Text] [Related]
4. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint modulation for non-small cell lung cancer.
Soria JC; Marabelle A; Brahmer JR; Gettinger S
Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
9. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
10. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
[TBL] [Abstract][Full Text] [Related]
12. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Rolfo C; Caglevic C; Santarpia M; Araujo A; Giovannetti E; Gallardo CD; Pauwels P; Mahave M
Adv Exp Med Biol; 2017; 995():97-125. PubMed ID: 28321814
[TBL] [Abstract][Full Text] [Related]
15. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
16. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
Marrone KA; Brahmer JR
Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
[TBL] [Abstract][Full Text] [Related]
19. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
Sgambato A; Casaluce F; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Drug Saf; 2016; 11(1):62-8. PubMed ID: 26412670
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
